Elizabeth Barrett

Elizabeth Barrett

DirectoratUroGen Pharma· In proxies 2022–2025

Pay in FY2025+4% from the year before · UroGen Pharma stock +119.9% the same year

Elizabeth Barrett was paid $4.3M in FY2025 (Dec), up 4%. UroGen Pharma stock rose 119.9% that year.

Pay$100 in the stock at the end of FY21 → $246
Pay is from the Summary Compensation Table of each UroGen Pharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Allogene TherapeuticsPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  2. UroGen PharmaPublic company · 4 yr
    • Chief Executive Officer2022 – Present · 4 yrStock in role +272%
  3. Allogene Therapeutics, Inc.Public company · 5 yr
    • Director2021 – Present · 5 yrNo stock prices for these years
  4. Sage Therapeutics, Inc.Public company · 7 yr
    • Director2019 – Present · 7 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?